Development and Validation of A LC–MS/MS Method for The Quantification of The Checkpoint Kinase 1 Inhibitor Sra737 in Human Plasma | Zendy

Monique Zangarini | Zendy; Philip Berry | Zendy; Julieann Sludden | Zendy; Florence I. Raynaud | Zendy; Udai Banerji | Zendy; Paul S. Jones | Zendy; David Edwards | Zendy; Gareth J. Veal | Zendy

Open Access

Development and Validation of A LC–MS/MS Method for The Quantification of The Checkpoint Kinase 1 Inhibitor Sra737 in Human Plasma

Author(s) -

Monique Zangarini,

Philip Berry,

Julieann Sludden,

Florence I. Raynaud,

Udai Banerji,

Paul S. Jones,

David Edwards,

Gareth J. Veal

Publication year - 2017

Publication title -

bioanalysis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.566

H-Index - 58

eISSN - 1757-6199

pISSN - 1757-6180

DOI - 10.4155/bio-2017-0043

Subject(s) - chromatography , protein precipitation , coefficient of variation , human plasma , chemistry

Aim: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC–MS/MS method for quantifying plasma concentrations of SRA737 was validated. Methods & results: Sample preparation involved protein precipitation with acetonitrile following addition of 13 C 15 N-deuterated SRA737 as internal standard. A rapid and selective method was fully validated across a range of 5–20,000 ng/ml, exhibiting good sensitivity, overall precision (expressed as coefficient of variation) ≤8.0% and accuracy 96–102%. Consistently high recovery was observed, with no matrix effect and a lower limit of quantitation of 5 ng/ml. Conclusion: A novel method for analyzing SRA737 in human plasma has been validated and is now being utilized for quantification of SRA737 in a Phase I trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research